Gesynta Pharma AB, a Swedish startup leveraging research from Karolinska Institutet, has raised €6 million (US$6.7 million) to advance a drug for the treatment of microvascular diseases in chronic inflammatory conditions through an upcoming phase I study. The investment, from Industrifonden and a group of private life sciences investors, will help the company illuminate the potential of GS-248, an asset acquired from Sweden's Orexo AB for treatment of an undisclosed orphan disease.